477 related articles for article (PubMed ID: 33133102)
41. Hepcidin and arterial stiffness in children with systemic lupus erythematosus and lupus nephritis: A cross-sectional study.
Atkinson MA; Joo S; Sule S
PLoS One; 2019; 14(3):e0214248. PubMed ID: 30925172
[TBL] [Abstract][Full Text] [Related]
42. Dickkopf-1 Is a Biomarker for Systemic Lupus Erythematosus and Active Lupus Nephritis.
Xue J; Yang J; Yang L; Zhou S; Ji C; Wang X; Yu N; Liu X; Chi S
J Immunol Res; 2017; 2017():6861575. PubMed ID: 28373995
[TBL] [Abstract][Full Text] [Related]
43. Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity.
Burcsár S; Toldi G; Kovács L; Szalay B; Vásárhelyi B; Balog A
Biomarkers; 2021 Jul; 26(5):443-449. PubMed ID: 33825610
[TBL] [Abstract][Full Text] [Related]
44. Serum and Urinary Interferon-Gamma-Inducible Protein 10 in Lupus Nephritis.
El-Gohary A; Hegazy A; Abbas M; Kamel N; Nasef SI
J Clin Lab Anal; 2016 Nov; 30(6):1135-1138. PubMed ID: 27184880
[TBL] [Abstract][Full Text] [Related]
45. Anti-C1q antibodies in lupus nephritis and their correlation with the disease activity.
Emad G; Al-Barshomy SM
Saudi J Kidney Dis Transpl; 2020; 31(2):342-352. PubMed ID: 32394906
[TBL] [Abstract][Full Text] [Related]
46. Interleukin-32γ: Possible association with the activity and development of nephritis in patients with systemic lupus erythematosus.
Kwon OC; Ghang B; Lee EJ; Hong S; Lee CK; Yoo B; Kim S; Kim YG
Int J Rheum Dis; 2019 Jul; 22(7):1305-1311. PubMed ID: 30941928
[TBL] [Abstract][Full Text] [Related]
47. Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment.
Davies JC; Midgley A; Carlsson E; Donohue S; Bruce IN; Beresford MW; Hedrich CM
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32723832
[TBL] [Abstract][Full Text] [Related]
48. Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis.
Puapatanakul P; Chansritrakul S; Susantitaphong P; Ueaphongsukkit T; Eiam-Ong S; Praditpornsilpa K; Kittanamongkolchai W; Avihingsanon Y
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31597273
[TBL] [Abstract][Full Text] [Related]
49. Galectin-3 binding protein links circulating microparticles with electron dense glomerular deposits in lupus nephritis.
Nielsen CT; Østergaard O; Rekvig OP; Sturfelt G; Jacobsen S; Heegaard NH
Lupus; 2015 Oct; 24(11):1150-60. PubMed ID: 25837289
[TBL] [Abstract][Full Text] [Related]
50. C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis.
Sjöwall C; Olin AI; Skogh T; Wetterö J; Mörgelin M; Nived O; Sturfelt G; Bengtsson AA
Autoimmunity; 2013 May; 46(3):205-14. PubMed ID: 23331132
[TBL] [Abstract][Full Text] [Related]
51. Serum uric acid levels are associated with lupus nephritis in patients with normal renal function.
Calich AL; Borba EF; Ugolini-Lopes MR; da Rocha LF; Bonfá E; Fuller R
Clin Rheumatol; 2018 May; 37(5):1223-1228. PubMed ID: 29353328
[TBL] [Abstract][Full Text] [Related]
52. Do circulating antibodies against C1q reflect the activity of lupus nephritis?
Smykał-Jankowiak K; Niemir ZI; Polcyn-Adamczak M
Pol Arch Med Wewn; 2011 Sep; 121(9):287-95. PubMed ID: 21860370
[TBL] [Abstract][Full Text] [Related]
53. Biomarkers in lupus nephritis.
Misra R; Gupta R
Int J Rheum Dis; 2015 Feb; 18(2):219-32. PubMed ID: 25884459
[TBL] [Abstract][Full Text] [Related]
54. Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis.
Kang EH; Moon KC; Lee EY; Lee YJ; Lee EB; Ahn C; Song YW
Lupus; 2009 Jan; 18(1):22-8. PubMed ID: 19074165
[TBL] [Abstract][Full Text] [Related]
55. Lupus nephritis: correlation of immunohistochemical expression of C4d, CD163-positive M2c-like macrophages and Foxp3-expressing regulatory T cells with disease activity and chronicity.
Allam M; Fathy H; Allah DA; Salem MAE
Lupus; 2020 Jul; 29(8):943-953. PubMed ID: 32580679
[TBL] [Abstract][Full Text] [Related]
56. Complement Alternative Pathway׳s Activation in Patients With Lupus Nephritis.
Song D; Guo WY; Wang FM; Li YZ; Song Y; Yu F; Zhao MH
Am J Med Sci; 2017 Mar; 353(3):247-257. PubMed ID: 28262211
[TBL] [Abstract][Full Text] [Related]
57. Worse Renal Presentation and Prognosis in Initial-Onset Lupus Nephritis than Early-Onset Lupus Nephritis.
Kwon OC; Park JH; Lee SW; Song JJ; Park YB; Park MC
Yonsei Med J; 2020 Nov; 61(11):951-957. PubMed ID: 33107238
[TBL] [Abstract][Full Text] [Related]
58. Urinary levels of sirtuin-1 associated with disease activity in lupus nephritis.
Olivares D; Perez-Hernandez J; Forner MJ; Perez-Soriano C; Tormos MC; Saez GT; Chaves FJ; Redon J; Cortes R
Clin Sci (Lond); 2018 Mar; 132(5):569-579. PubMed ID: 29440621
[TBL] [Abstract][Full Text] [Related]
59. Interleukin-35 as a New Biomarker of Renal Involvement in Lupus Nephritis Patients.
He D; Liu M; Liu B
Tohoku J Exp Med; 2018 Apr; 244(4):263-270. PubMed ID: 29576585
[TBL] [Abstract][Full Text] [Related]
60. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.
Schwartz N; Rubinstein T; Burkly LC; Collins CE; Blanco I; Su L; Hojaili B; Mackay M; Aranow C; Stohl W; Rovin BH; Michaelson JS; Putterman C
Arthritis Res Ther; 2009; 11(5):R143. PubMed ID: 19785730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
